New: a trial court in 1 of every 10 U.S. counties. Read the post
Court Rules
All enforcement actions
InvestigationLow Risk

Texas AG Launches Investigations into Women's Product Brands Over Toxic Chemicals

TampaxJuly 27, 2026Texas Attorney General

Summary

Texas Attorney General Ken Paxton announced industry-wide investigations into feminine care and cosmetic product brands, including Tampax, Kotex, L., and LOLA, over potential deceptive trade practices related to undisclosed toxic chemicals and heavy metals in their products. The investigations focus on whether consumers were misled about product safety and ingredient composition under the Texas Deceptive Trade Practices Act.

Remedy

No remedies imposed; investigation ongoing.

Contract Impact

In-house legal teams should review vendor and supplier agreements for representations and warranties regarding product safety and ingredient compliance, particularly clauses related to disclosure of toxic substances and compliance with state deceptive trade practices laws. Additionally, marketing and advertising agreements should be examined to ensure claims about product safety and 'non-toxic' labels are substantiated and not misleading.

Contract Search Terms

toxic chemicalsdeceptive trade practicesproduct safetyheavy metalsingredient disclosuremisleading advertisingfeminine care productslip productsCivil Investigative Demand

Laws Cited

Texas Deceptive Trade Practices Act (DTPA)

Violation Types

Entity Details

Entity

Tampax

Industry

Retail

Official Sources

Source Evidence

Entity Name
"the OAG has issued Civil Investigative Demands (“CIDs”) to Tampax, Kotex, L., and LOLA."
Fine Amount
"No monetary penalty is mentioned in the press release."
Laws Cited
"These investigations will focus on potential violations of the Texas Deceptive Trade Practices Act (“DTPA”)"
Violation Types
"whether consumers were misled regarding the safety, quality, or chemical composition of these products."

Related Enforcement Actions

TX

PDD Holdings, Inc. and WhaleCo Inc. (doing business as Temu)

$3.0M

Texas Attorney General Ken Paxton announced a settlement requiring Temu to protect Texans’ sensitive personal data from exposure to the Chinese Communist Party and to strengthen product-safety practices. Temu must pay Texas $3 million, comply with data-security requirements backed by a potential $8 million annual penalty, conduct annual independent product testing, and take specified action on products found to contain harmful substances.

TX

Albertsons Companies, Inc.

$773.0M

Texas Attorney General Ken Paxton announced that a multistate coalition had secured an opioid settlement with Albertsons, which would require the grocery chain to pay more than $773 million nationally once final. Texas and its political subdivisions may receive up to $57.8 million for opioid abatement; the release does not identify privacy violations.

TX

Gerber Products Company and Nestlé USA, Inc.

Texas Attorney General Ken Paxton sued Gerber Products Company and Nestlé USA, Inc., alleging that Gerber made deceptive safety and testing claims while its baby food contained dangerous levels of toxic heavy metals. The lawsuit asserts claims under the Texas Deceptive Trade Practices Act; the release does not report a settlement, monetary penalty, or court order.

TX

Rubinsky Roofing LLC

$1.5M

The Texas Attorney General obtained a judgment holding Rubinsky Roofing LLC liable for 27 violations of the Texas Deceptive Trade Practices Act, including deceptive practices involving older consumers and payment for unnecessary or unfinished repairs. The judgment requires more than $1.5 million in civil penalties, allocates at least $500,000 to consumer restitution, and permanently bars the company and its owner from the practices at issue.

TX

UnitedHealth Group, Inc.

The Texas Attorney General opened an investigation into UnitedHealth Group over allegations that its insurance-benefit administration and patient-care decisions denied Texans medically necessary healthcare. The AG issued Civil Investigative Demands to collect evidence; the release announces no penalty or remedy.

TX

Tris Pharmaceuticals

$7.5M

Texas Attorney General Ken Paxton announced a $7.5 million settlement with Tris Pharmaceuticals over alleged misrepresentations about the efficacy of Dyanavel XR, an ADHD drug marketed for children. The release says the company overstated the drug’s efficacy and directed sales representatives to make misleading claims to doctors, including Medicaid providers.